Gail D Anderson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4843240/publications.pdf

Version: 2024-02-01

51 papers	3,344 citations	147726 31 h-index	182361 51 g-index
52 all docs	52 docs citations	52 times ranked	3699 citing authors

#	Article	IF	Citations
1	Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction. Pharmacotherapy, 2019, 39, 756-766.	1.2	7
2	Methods of Estimating Kidney Function for Drug Dosing in Special Populations. Clinical Pharmacokinetics, 2018, 57, 943-976.	1.6	16
3	Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy. Drugs and Aging, 2018, 35, 687-698.	1.3	8
4	AES Position Statement on Generic Substitution of Antiepileptic Drugs. Epilepsy Currents, 2016, 16, 209-211.	0.4	36
5	Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clinical Pharmacokinetics, 2016, 55, 1353-1368.	1.6	114
6	Combination Therapies for Traumatic Brain Injury: Retrospective Considerations. Journal of Neurotrauma, 2016, 33, 101-112.	1.7	56
7	Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model. AAPS Journal, 2015, 17, 1255-1267.	2.2	12
8	A behavioral and histological comparison of fluid percussion injury and controlled cortical impact injury to the rat sensorimotor cortex. Behavioural Brain Research, 2015, 294, 254-263.	1.2	25
9	Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects. CNS Drugs, 2015, 29, 669-681.	2.7	23
10	A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. Journal of Neurotrauma, 2015, 32, 765-779.	1.7	31
11	Comparison of the Effect of Minocycline and Simvastatin on Functional Recovery and Gene Expression in a Rat Traumatic Brain Injury Model. Journal of Neurotrauma, 2014, 31, 961-975.	1.7	29
12	Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment. Clinical Pharmacokinetics, 2014, 53, 29-49.	1.6	26
13	Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol). Clinical Pharmacokinetics, 2014, 53, 1115-1136.	1.6	70
14	Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model. Frontiers in Pharmacology, 2013, 4, 129.	1.6	17
15	A Comparison of the Effects of Nicotinamide and Progesterone on Functional Recovery of Cognitive Behavior following Cortical Contusion Injury in the Rat. Journal of Neurotrauma, 2012, 29, 2823-2830.	1.7	34
16	Current oral and non-oral routes of antiepileptic drug delivery. Advanced Drug Delivery Reviews, 2012, 64, 911-918.	6.6	68
17	The Effect of Progesterone Dose on Gene Expression after Traumatic Brain Injury. Journal of Neurotrauma, 2011, 28, 1827-1843.	1.7	44
18	Developmental Pharmacokinetics. Seminars in Pediatric Neurology, 2010, 17, 208-213.	1.0	45

#	Article	IF	Citations
19	Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytotherapy Research, 2010, 24, 1442-1446.	2.8	18
20	Sustained Delivery of Nicotinamide Limits Cortical Injury and Improves Functional Recovery Following Traumatic Brain Injury. Oxidative Medicine and Cellular Longevity, 2010, 3, 145-152.	1.9	44
21	Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach. Pharmacotherapy, 2009, 29, 680-690.	1.2	119
22	Haptoglobin phenotype and apolipoprotein E polymorphism: Relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury. Epilepsy and Behavior, 2009, 16, 501-506.	0.9	39
23	Effect of Pregnancy on the Pharmacokinetics of Antihypertensive Drugs. Clinical Pharmacokinetics, 2009, 48, 159-168.	1.6	43
24	Pharmacokinetic, Pharmacodynamic, and Pharmacogenetic Targeted Therapy of Antiepileptic Drugs. Therapeutic Drug Monitoring, 2008, 30, 173-180.	1.0	56
25	Effect of Time, Injury, Age and Ethanol on Interpatient Variability in Valproic Acid Pharmacokinetics after Traumatic Brain Injury. Clinical Pharmacokinetics, 2007, 46, 307-318.	1.6	10
26	Using pharmacokinetics to predict the effects of pregnancy and maternalâ€“infant transfer of drugs during lactation. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 947-960.	1.5	71
27	Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytotherapy Research, 2005, 19, 801-803.	2.8	35
28	Sex and Racial Differences in Pharmacological Response: Where Is the Evidence? Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics. Journal of Women's Health, 2005, 14, 19-29.	1.5	250
29	Pregnancy-Induced Changes in Pharmacokinetics. Clinical Pharmacokinetics, 2005, 44, 989-1008.	1.6	538
30	Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology, 2004, 63, S3-8.	1.5	113
31	Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Advances in Chronic Kidney Disease, 2004, 11, 357-60.	0.6	4
32	Effect of valproate on hemostatic function in patients with traumatic brain injury. Epilepsy Research, 2003, 57, 111-119.	0.8	15
33	Drug Interaction Potential of Soy Extract and Panax Ginseng. Journal of Clinical Pharmacology, 2003, 43, 643-648.	1.0	86
34	Drug Interaction Potential of Soy Extract and Panax Ginseng. Journal of Clinical Pharmacology, 2003, 43, 643-648.	1.0	1
35	Drug interaction potential of soy extract and Panax ginseng. Journal of Clinical Pharmacology, 2003, 43, 643-8.	1.0	25
36	Children Versus Adults: Pharmacokinetic and Adverse-Effect Differences. Epilepsia, 2002, 43, 53-59.	2.6	158

#	Article	IF	Citations
37	Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Research, 2002, 49, 211-217.	0.8	38
38	Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. Journal of Gender-specific Medicine, 2002, 5, 25-33.	0.1	14
39	Antiepileptogenic Agents. Drugs, 2001, 61, 1045-1055.	4.9	77
40	Tramadol and Seizures: A Surveillance Study in a Managed Care Population. Pharmacotherapy, 2000, 20, 1423-1431.	1.2	138
41	St John's Wort: Effect on CYP3A4 activity. Clinical Pharmacology and Therapeutics, 2000, 67, 451-457.	2.3	277
42	Differences in the Urinary Excretion of 6-Î²-Hydroxycortisol/Cortisol between Asian and Caucasian Women. Journal of Clinical Pharmacology, 1999, 39, 578-582.	1.0	49
43	Increases in metabolism of valproate and excretion of 6 Î² â€hydroxycortisol in patients with traumatic brain injury. British Journal of Clinical Pharmacology, 1998, 45, 101-105.	1.1	12
44	Therapeutic Monitoring: Revised Winterâ€“Tozer Equation for Normalized Phenytoin Concentrations in Trauma and Elderly Patents with Hypoalbuminemia. Annals of Pharmacotherapy, 1997, 31, 279-284.	0.9	51
45	Bidirectional interaction of valproate and lamotrigine in healthy subjects*. Clinical Pharmacology and Therapeutics, 1996, 60, 145-156.	2.3	119
46	Drug Interactions With Antiepileptic Agents. CNS Drugs, 1994, 2, 268-279.	2.7	10
47	Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver. Epilepsia, 1994, 35, 221-225.	2.6	41
48	Stiripentol in Atypical Absence Seizures in Children: An Open Trial. Epilepsia, 1993, 34, 305-311.	2.6	62
49	Effect of Valproate Dose on Formation of Hepatotoxic Metabolites. Epilepsia, 1992, 33, 736-742.	2.6	48
50	The effect of valproate on the metabolism of phenobarbital in the rat. Pharmaceutical Research, 1992, 09, 1622-1628.	1.7	8
51	Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clinical Pharmacology and Therapeutics, 1990, 48, 225-235.	2.3	113